Drugs / AKTi-treated TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02489266 | Jun 2015 → Jun 2016 | metastatic melanoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKTi-treated TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02489266 ↗ |
| Action | Inhibit | “a pharmacologic inhibitor of AKT” NCT02489266 ↗ |
| Modality | Cell therapy | “autologous tumor-infiltrating lymphocytes (TIL)” NCT02489266 ↗ |
| Route | Intravenous | “cells will be infused intravenously (IV)” NCT02489266 ↗ |